Results 161 to 170 of about 1,404,244 (275)

A Systematic Study of GelMA‐Carbopol Bioinks for High‐Fidelity Extrusion 3D Bioprinting at Physiological Temperatures

open access: yesAdvanced Healthcare Materials, EarlyView.
Gonzalez Martinez and collaborators develop a strategy to formulate high performance GelMA‐based bioinks with low solids contents. The resulting bioinks enable 3D bioprinting at 37 °C of high‐fidelity structures with tunable mechanical properties that support high cell viability and function.
David A. González‐Martínez   +8 more
wiley   +1 more source

A Novel Drug‐Loaded Porous Parylene Electrode for Targeted Anti‐Inflammatory Therapy and Hearing Preservation in Cochlear Implantation

open access: yesAdvanced Healthcare Materials, EarlyView.
A porous parylene‐coated electrode loaded with dexamethasone was developed to reduce inflammation after cochlear implantation. In guinea pigs, the device provided sustained drug release, maintained biocompatibility, improved auditory brainstem response thresholds, and reduced inflammatory cell infiltration and TNF‐α expression.
Chi‐Chieh Chang   +11 more
wiley   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

open access: yesAdvanced Healthcare Materials, EarlyView.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave   +8 more
wiley   +1 more source

Overcoming Photodynamic Therapy Resistance: GSH‐Responsive AIE Photosensitizer‐Hydroxycamptothecin Nanoliposomes for Extrahepatic Cholangiocarcinoma

open access: yesAdvanced Healthcare Materials, EarlyView.
A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Yong Qu   +19 more
wiley   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

open access: yesAdvanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy